Comparison of sodium hyaluronate 2.3% and 1.6% (Healon5 and Amvisc Plus)in Corneal edema and intraocular pressure after cataract surgerycomparison of sodium hyaluronate 2.3% and 1.6% (Healon5 and Amvisc Plus)in Corneal edema and intraocular pressure after

Comparison of BD MultiviscTM with the soft shell technique in cases with hard lens nucleus and Fuchs endothelial dystrophy.

Article specifications

This randomize clinical trial was published in 2007 in European journal of ophthalmology (IF 2017:1.381) by Italian ophthalmologists. In this article the efficacy of 2.5% sodium hyaluronate (BD MultiviscTM) with the soft shell technique in reducing corneal endothelial cell damage during cataract phacoemulsification in patients with hard lens nucleus (3+) and cornea guttata was compared.

30 patients included 37 eyes divided in 2 groups:  Group A 19 eyes, had phacoemulsification and intraocular lens (IOL) implantation with the soft-shell technique with Biolon® (sodium hyaluronate 1%) and Viscoat® (sodium hyaluronate 3%–chondroitin sulfate 4%); Group B, 18 eyes, had BD MultiviscTM alone. Patients were evaluated preoperatively and after 1, 15, 90, and 180 days, checked for best-corrected visual acuity (BCVA), intraocular pressure (IOP), central corneal thickness, and corneal endothelial density.

Results

Postoperative BCVA, IOP, central corneal thickness and endothelial density was similar in both group A and B.

In conclusion this clinical trial showed that both the soft-shell technique and MultiviscTM are effective in protecting endothelial layer and are safe in eyes with Fuchs dystrophy and hard lens nucleus.